THERAPY DOSSIER · th-4076702fdbe7

Caveolin-1 scaffolding domain peptide (CSP)

Drug · Peptide (caveolin-1 scaffolding domain peptide); no confident ChEMBL match, preclinical

Evidence & regulatory context

Mechanism: Peptide (caveolin-1 scaffolding domain peptide); no confident ChEMBL match, preclinical
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25596429 ↗2015Reported benefit

Role of p53-fibrinolytic system cross-talk in the regulation of quartz-induced lung injury.

MouseChemical/toxinC57BL/6 wild-type and knockout strainsFemale

Model: Silica (crystalline quartz) dust exposure causing lung injury and silicosis

Silica exposure increased alveolar epithelial cell apoptosis with induction of p53 and PAI-1 and suppression of uPA. CSP inhibited PAI-1, restored uPA and prevented apoptosis by suppressing p53 activation.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…